SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data
SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...
HKG: 3681
SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...
SinoMab BioScience’s SM17 Atopic Dermatitis Drug Reaches First Patient Milestone in Phase Ib Trial
SinoMab BioScience Ltd (HKG: 3681), a biotech firm based in Hong Kong, has announced the...
SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA
SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...
SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17
Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...
SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...
SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...
SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products...
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III...
SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial
Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products...